ArticleFrontiers in oncology2026
ABRAXAS1-HELQ is a candidate class-matched reference chimeric RNA and contributes to prostate cell motility through MCOLN2.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: RT-qPCR is widely used for RNA expression quantification, and reliable normalization requires appropriate reference genes. Because different RNA classes display distinct expression characteristics, class-matched internal controls are essential for reliable quantification. While class-matched reference genes have been established for microRNAs and circular RNAs, stable reference genes for chimeric RNAs in the prostate remain lacking, limiting the accuracy of expression analyses. Recent evidence indicates that chimeric RNAs also exist under physiological conditions, suggesting that some chimeric RNAs may function as housekeeping-like molecules. Methods: RNA sequencing data from the TCGA and CPGEA prostate cancer cohorts were analyzed to identify candidate class-matched reference chimeric RNAs, followed by experimental evaluation in prostate cell lines and prostate tissue samples. Candidate chimeric RNAs were experimentally validated using touchdown PCR, gel electrophoresis, Sanger sequencing, and RT-qPCR. Subcellular localization and biological functions were further evaluated by nuclear-cytoplasmic fractionation, transcriptome analysis, and functional assays. Results: Analysis of chimeric RNAs shared between TCGA and CPGEA identified 37 candidate chimeric RNAs without a statistically detectable difference between prostate cancer and matched adjacent tissues. ABRAXAS1-HELQ was detectable in the pooled clinical sample, showed a comparatively consistent expression pattern across nine prostate-derived cell lines, and showed no significant change under selected experimental conditions in three cell lines. siRNA-mediated reduction of ABRAXAS1-HELQ was associated with reduced cell migration, with MCOLN2 identified as a potential downstream mediator. Conclusion: ABRAXAS1-HELQ represents a candidate class-matched reference chimeric RNA with relatively consistent expression under the tested experimental conditions and serves as a potential reference molecule for chimeric RNA quantification in prostate-related studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.